期刊文献+
共找到11篇文章
< 1 >
每页显示 20 50 100
肝癌患者经导管动脉化疗栓塞后发生栓塞综合征的影响因素分析
1
作者 李丽敏 王璐 +2 位作者 曹阳博 刘栋利 陈鹏飞 《癌症进展》 2024年第1期72-75,共4页
目的探讨肝癌患者经导管动脉化疗栓塞(TACE)后发生栓塞综合征的影响因素。方法根据是否发生栓塞综合征将120例行TACE治疗的肝癌患者分为未发生组(n=63)和发生组(n=57)。比较两组患者的临床特征,采用Logistic回归模型分析肝癌患者TACE治... 目的探讨肝癌患者经导管动脉化疗栓塞(TACE)后发生栓塞综合征的影响因素。方法根据是否发生栓塞综合征将120例行TACE治疗的肝癌患者分为未发生组(n=63)和发生组(n=57)。比较两组患者的临床特征,采用Logistic回归模型分析肝癌患者TACE治疗后发生栓塞综合征的影响因素。结果发生组和未发生组患者的性别、心脏病病史、美国东部肿瘤协作组(ECOG)体力状况(PS)评分比较,差异均有统计学意义(P﹤0.05)。发生组和未发生组患者的年龄、体重指数、肿瘤数目、肿瘤直径、文化程度、高血压/糖尿病病史、术前疼痛情况、甲胎蛋白水平、Child-Pugh分级、巴塞罗那分期比较,差异均无统计学意义(P﹥0.05)。多因素Logistic回归分析结果显示,女性是肝癌患者TACE治疗后发生栓塞综合征的独立保护因素(P﹤0.05),有心脏病病史、ECOG PS评分为1分均是肝癌患者TACE治疗后发生栓塞综合征的独立危险因素(P﹤0.05)。结论性别、心脏病病史、ECOG PS均是肝癌患者TACE治疗后发生栓塞综合征的影响因素,临床应考虑上述因素,制订针对性的预防措施,从而改善患者预后。 展开更多
关键词 肝癌 经导管动脉化疗栓塞 美国东部肿瘤协作组体力状况评分 栓塞综合征
下载PDF
Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients 被引量:2
2
作者 Kuruswamy Thurai Prasad Harpreet Kaur +3 位作者 Valliappan Muthu Ashutosh Nath Aggarwal Digambar Behera Navneet Singh 《World Journal of Clinical Oncology》 CAS 2018年第7期140-147,共8页
AIM To establish the Karnofsky performance status(KPS) categories which would facilitate the interconversion of the KPS scale to the Eastern Cooperative Oncology Group(ECOG) performance status(PS) scale.METHODS This w... AIM To establish the Karnofsky performance status(KPS) categories which would facilitate the interconversion of the KPS scale to the Eastern Cooperative Oncology Group(ECOG) performance status(PS) scale.METHODS This was a retrospective analysis of all patients attending the lung cancer clinic at a tertiary care center over a 5-year period(September 2009 to August 2014). All patients were assessed with both KPS and ECOG PS scales at each visit. Correlation between KPS and ECOG PS was assessed using Spearman's correlation coefficient. KPS categories equivalent to ECOG PS scores were compared using hit rate and weighted kappa(κw).RESULTS A total of 1501 patients were assessed over the study period, providing 5844 paired KPS and ECOG PS assessments. The study cohort had a mean(standard deviation; SD) age of 58.4(10.8) years, with the majority being current or ex-smokers(76.9%) and males(82.3%). Non-small cell lung cancer was the most common histological type(n = 1196, 79.7%) with the majority having advanced(stage ⅢB/Ⅳ) disease(83.4%). Mean baseline KPS and ECOG PS scores were 77.6(SD = 14.4) and 1.5(SD = 1) respectively. The most frequent KPS score was 80(29%), and the most frequent ECOG PS score was 1(43%). The overall correlation between KPS and ECOG PS was good(Spearman r =-0.84, P < 0.0001) but ranged from-0.727 to-0.972 between visits. KPS categories derived from our cohort [10-40(ECOG 4), 50-60(ECOG 3), 70(ECOG 2), 80-90(ECOG 1), 100(ECOG 0)] performed better [hit rate 78.1%, κw = 0.749(0.736-0.762) P < 0.0001] than those suggested in the past literature.CONCLUSION The current study provides the largest set of paired KPS-ECOG assessments to date. We suggest that the KPS categories 10-40, 50-60, 70, 80-90, and 100 are equivalent to ECOG PS categories of 4, 3, 2, 1, and 0 respectively. 展开更多
关键词 Karnofsky performance status eastern cooperative oncology group performance status Lung cancer CHEMOTHERAPY
下载PDF
PD-1抑制剂治疗肝癌患者的临床疗效及ECOG-PS评分联合Child-Pugh分级对肿瘤超进展的预测价值 被引量:3
3
作者 陈方红 刘娱 边界 《广西医学》 CAS 2023年第15期1800-1806,共7页
目的探讨程序性死亡受体1(PD-1)抑制剂治疗肝癌患者的临床疗效,以及美国东部肿瘤协作组体力状况(ECOG-PS)评分联合Child-Pugh分级对肿瘤超进展的预测价值。方法选择100例肝癌患者,所有患者接受PD-1抑制剂治疗。根据治疗后是否出现肿瘤... 目的探讨程序性死亡受体1(PD-1)抑制剂治疗肝癌患者的临床疗效,以及美国东部肿瘤协作组体力状况(ECOG-PS)评分联合Child-Pugh分级对肿瘤超进展的预测价值。方法选择100例肝癌患者,所有患者接受PD-1抑制剂治疗。根据治疗后是否出现肿瘤超进展将患者分为超进展组(n=18)和未超进展组(n=82),分析PD-1抑制剂治疗肝癌患者的临床疗效。采用受试者工作特征曲线评价Child-Pugh分级、ECOG-PS评分对肝癌患者发生肿瘤超进展的预测价值。采用多因素Logistic回归模型分析肝癌患者发生肿瘤超进展的独立影响因素,构建列线图预测模型并进行验证。结果PD-1抑制剂治疗后肝癌患者的疾病控制率为42.00%,肿瘤超进展发生率为18.00%。未超进展组与超进展组患者的年龄、饮酒史、肝炎病史、肿瘤直径、血管侵犯情况、远处转移情况、转移部位数量、甲胎蛋白水平、中性粒细胞与淋巴细胞比值(NLR)、Child-Pugh分级、ECOG-PS评分的差异有统计学意义(P<0.05)。Child-Pugh分级联合ECOG-PS评分预测肝癌患者发生肿瘤超进展的受试者工作特征曲线下面积、敏感度、特异度、阳性预测值、阴性预测值高于Child-Pugh分级、ECOG-PS评分单独预测(P<0.05)。多因素Logistic回归分析结果显示,年龄、远处转移情况、甲胎蛋白水平、NLR、Child-Pugh分级、ECOG-PS评分是肝癌患者出现肿瘤超进展的独立影响因素(P<0.05),根据上述影响因素构建的列线图预测模型预测肝癌患者出现肿瘤超进展具有良好的区分度和校准度。结论PD-1抑制剂治疗肝癌患者的疗效显著。ECOG-PS评分联合Child-Pugh分级对肝癌患者PD-1抑制剂治疗后发生肿瘤超进展具有较好的预测价值。年龄、远处转移情况、甲胎蛋白水平、NLR、Child-Pugh分级、ECOG-PS评分是肝癌患者发生肿瘤超进展的独立影响因素,基于上述因素所构建的列线图预测模型可为临床评估肝癌患者发生肿瘤超进展提供参考。 展开更多
关键词 肝癌 程序性死亡受体1 美国东部肿瘤协作组体力状况评分 CHILD-PUGH分级 疗效 肿瘤超进展 影响因素
下载PDF
简化老年综合评估分级在老年女性乳腺癌患者中的应用价值 被引量:6
4
作者 林燕 宋雨 +7 位作者 徐颖 姚儒 周星彤 王常珺 黄欣 王雪霏 曹希 孙强 《中国医学科学院学报》 CAS CSCD 北大核心 2021年第3期395-401,共7页
目的评估简化老年综合评估(aCGA)分级在老年女性乳腺癌患者中应用价值。方法将综合老年评估(CGA)8个方面的简化量表内容和得分纳入aCGA评估表,根据评估得分划分为A、B、C 3个级别。以2018年6月至2020年1月北京协和医院收治的70岁及以上... 目的评估简化老年综合评估(aCGA)分级在老年女性乳腺癌患者中应用价值。方法将综合老年评估(CGA)8个方面的简化量表内容和得分纳入aCGA评估表,根据评估得分划分为A、B、C 3个级别。以2018年6月至2020年1月北京协和医院收治的70岁及以上的老年女性乳腺癌患者为研究对象,分别做美国东部肿瘤协作组(ECOG)评分及aCGA分级,并对两种评估方法的结果进行比较。结果162例患者中,111例(68.5%)aCGA分级为A级,43例(26.5%)为B级,8例(5.0%)为C级;131例(80.9%)伴有并发疾病,最常见的并发症依次为高血压(n=89)、心血管疾病(n=47)、糖尿病(n=39)。ECOG评分0~1分133例(82.0%),2分24例(14.8%),3分5例(3.2%),无4分及以上病例。ECOG体能状态良好133例(82.0%),不良29例;aCGA分级健康状态良好111例,不良51例;两组相比差异有统计学意义(χ^(2)=14.24,P<0.001)。结论aCGA分级较ECOG评分能更全面评估老年女性乳腺癌患者的综合健康状况,可应用于70岁及以上的老年乳腺癌患者。 展开更多
关键词 老年 乳腺癌 综合评估 东部肿瘤协作组评分
下载PDF
Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer:a systematic review 被引量:4
5
作者 Wen-Jun Chen Da-Ming Kong Liang Li 《Asian Journal of Andrology》 SCIE CAS CSCD 2021年第2期163-169,共7页
Eastern Cooperative Oncology Group(ECOG)performance status and Gleason score are commonly investigated factors for overall survival(OS)in men with castration-resistant prostate cancer(CRPC).However,there is a lack of ... Eastern Cooperative Oncology Group(ECOG)performance status and Gleason score are commonly investigated factors for overall survival(OS)in men with castration-resistant prostate cancer(CRPC).However,there is a lack of consistency regarding their prognostic or predictive value for OS.Therefore,we performed this meta-analysis to assess the associations of ECOG performance status and Gleason score with OS in CRPC patients and compare the two markers in patients under different treatment regimens or with different chemotherapy histories.A systematic literature review of monotherapy studies in CRPC patients was conducted in the PubMed database until May 2019.The data from 8247 patients in 34 studies,including clinical trials and real-world data,were included in our meta-analysis.Of these,twenty studies reported multivariate results and were included in our main analysis.CRPC patients with higher ECOG performance statuses(≥2)had a significantly increased mortality risk than those with lower ECOG performance statuses(<2),hazard ratio(HR):2.10,95%confidence interval(CI):1.68-2.62,and P<0.001.The synthesized HR of OS stratified by Gleason score was 1.01,with a 95%CI of 0.62-1.67(Gleason score≥8 vs<8).Subgroup analysis showed that there was no significant difference in pooled HRs for patients administered taxane chemotherapy(docetaxel and cabazitaxel)and androgen-targeting therapy(abiraterone acetate and enzalutamide)or for patients with different chemotherapy histories.ECOG performance status was identified as a significant prognostic factor in CRPC patients,while Gleason score showed a weak prognostic value for OS based on the available data in our meta-analysis. 展开更多
关键词 castration-resistant prostate cancer eastern cooperative oncology group performance status Gleason score META-ANALYSIS overall survival
原文传递
健脾活血中药联合化疗治疗大肠癌术后患者临床观察 被引量:8
6
作者 展鹏远 《新中医》 CAS 2017年第4期116-118,共3页
目的:观察健脾活血中药联合化疗在大肠癌术后治疗中的临床疗效。方法:选择76例大肠癌术后患者为研究对象,以随机数字表法分为2组各38例,对照组单纯采用化疗治疗,观察组采用健脾活血中药联合化疗治疗,对2组患者生存状态、生活质量、不良... 目的:观察健脾活血中药联合化疗在大肠癌术后治疗中的临床疗效。方法:选择76例大肠癌术后患者为研究对象,以随机数字表法分为2组各38例,对照组单纯采用化疗治疗,观察组采用健脾活血中药联合化疗治疗,对2组患者生存状态、生活质量、不良反应发生情况等进行观察。结果:观察组患者6月死亡率15.79%,中位生存时间(26.12±5.18)月,对照组患者6月死亡率39.47%,中位生存时间(20.67±8.44)月,2组死亡率、中位生存时间分别比较,差异均有统计学意义(P<0.01);治疗后,观察组Karnofsky评分较对照组高,美国中部肿瘤协作组(ECOG)评分较对照组低,差异均有统计学意义(P<0.01);观察组治疗后不良反应程度低于对照组,差异有统计学意义(P<0.05)。结论:健脾活血中药配合化疗可延长大肠癌患者术后生存时间,也能减轻化疗不良反应,对提高患者生活质量具有重要作用。 展开更多
关键词 大肠癌术后 中医疗法 健脾活血 化学疗法 6月死亡率 中位生存时间 KARNOFSKY评分 美国中部肿瘤协作组(ECOG)
原文传递
护士主导的护理措施在肺癌化疗患者中的应用 被引量:1
7
作者 杨瑞 吴海云 +2 位作者 罗丹 杨乐 郭丽君 《实用临床医学(江西)》 CAS 2022年第3期79-82,共4页
目的探讨以护士主导的护理措施在肺癌化疗患者中的应用效果。方法采取随机数字表法将100例肺癌化疗患者分为对照组和试验组,每组50例。对照组采用常规护理模式,试验组在对照组的基础上采用以护士主导的护理措施。比较2组生活质量量表(QL... 目的探讨以护士主导的护理措施在肺癌化疗患者中的应用效果。方法采取随机数字表法将100例肺癌化疗患者分为对照组和试验组,每组50例。对照组采用常规护理模式,试验组在对照组的基础上采用以护士主导的护理措施。比较2组生活质量量表(QLQ-C30)评分、美国东部肿瘤协作组(ECOG)活动状态量表评分和医院焦虑抑郁量表(HAD)评分。结果与对照组比较,试验组QLQ-C30评分显著提高(P<0.05),ECOG和HAD评分显著降低(均P<0.05)。结论对肺癌化疗患者采用以护士为主导的护理措施,可以提高患者生活质量和化疗耐受性,并改善其焦虑抑郁情绪。 展开更多
关键词 护士主导 化疗 肺癌 生活质量量表 活动状态评分表 焦虑抑郁量表
下载PDF
Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg 被引量:6
8
作者 Anne Katrin Berger Stefanie Zschaebitz +2 位作者 Christine Komander Dirk Jger Georg Martin Haag 《World Journal of Gastroenterology》 SCIE CAS 2015年第16期4911-4918,共8页
AIM:To investigate the outcome of palliative chemotherapy in old patients with gastroesophageal cancer at the National Center for Tumor Diseases,Heidelberg.METHODS:Using a prospectively generated database,we retrospec... AIM:To investigate the outcome of palliative chemotherapy in old patients with gastroesophageal cancer at the National Center for Tumor Diseases,Heidelberg.METHODS:Using a prospectively generated database,we retrospectively analyzed 55 patients≥70years under palliative chemotherapy for advanced gastroesophageal cancer at the outpatient clinic of the National Center for Tumor Diseases Heidelberg,Germany between January 2006 and December2013.Further requirements for inclusion were(1)histologically proven diagnosis of gastroesophageal cancer;(2)advanced(metastatic or inoperable)disease;and(3)no history of radiation or radiochemotherapy.The clinical information included Eastern Cooperative Oncology Group performance status(ECOG PS),presence and site of metastases at diagnosis,date of previous surgery and perioperative chemotherapy,start and stop date of first-line treatment,toxicities and consecutive dosage reductions of first-line treatment,response to first-line therapy,date of progression,usage of second-line therapies and date and cause of death.Survival times[progression-free survival(PFS),overall survival(OS)and residual survival(RS)]were calculated.Toxicity and safety were examined.Prognostic factors including ECOG PS,age and previousperioperative treatment were analyzed.RESULTS:Median age of our cohort was 76 years.86%of patients received a combination of two cytotoxic drugs.76 percent of patients had an oxaliplatin-based first-line therapy with the oxaliplatin and 5-fluorouracil regimen being the predominantely chosen regimen(69%).Drug modifications due to toxicity were necessary in 56%of patients,and 11%of patients stopped treatment due to toxicities.Survival times of our cohort are in good accordance with the major phaseⅢtrials that included mostly younger patients:PFS and OS were 5.8 and 9.5 mo,respectively.Survival differed significantly between patient groups with low(≤1)and high(≥2)ECOG PS(12.7 mo vs 3.8 mo,P<0.001).Very old patients(≥75 years)did not show a worse outcome in terms of survival.Patients receiving secondline treatment(51%)had a significantly longer RS than patients with best supportive care(6.8 vs 1.4 mo,P=0.001).Initial ECOG PS was a strong prognostic factor for PFS,OS and RS.CONCLUSION:Old patients with non-curable gastroesophageal cancer should be offered chemotherapy,and ECOG PS is a tool for balancing benefit and harm upfront.Second-line treatment is reasonable. 展开更多
关键词 GASTROESOPHAGEAL cancer OLD PATIENTS PALLIATIVE chemotherapy Toxicity eastern cooperativeoncology group performance status
下载PDF
自体骨髓干细胞移植治疗慢加急性乙型肝炎肝衰竭患者疗效初步研究 被引量:4
9
作者 宋玉 王芳 《实用肝脏病杂志》 CAS 2020年第3期388-391,共4页
目的探讨采取自体骨髓干细胞移植治疗慢加急性乙型肝炎肝衰竭(HBV-ACLF)患者的疗效。方法2017年5月~2018年12月在我院肝肾内科就诊的94例HBV-ACLF患者,被随机分为对照组47例和观察组47例,在内科综合治疗的基础上分别给予血浆透析滤过(P... 目的探讨采取自体骨髓干细胞移植治疗慢加急性乙型肝炎肝衰竭(HBV-ACLF)患者的疗效。方法2017年5月~2018年12月在我院肝肾内科就诊的94例HBV-ACLF患者,被随机分为对照组47例和观察组47例,在内科综合治疗的基础上分别给予血浆透析滤过(PDF)和PDF联合经肝动脉自体骨髓干细胞移植治疗。采用美国东部肿瘤协作组评分(ECOG)和终末期肝病模型(MELD)评分评价生活质量和肝功能状态。结果在治疗24周和48周时,观察组生存率分别为72.3%和53.2%,均显著高于对照组的48.9%和31.9%(P<0.05);在治疗24周末,34例观察组生存患者血清白蛋白(ALB)水平为(35.8±3.9)g/L,显著高于25例对照组【(32.3±3.5)g/L,P<0.05】;在治疗24周和48周时,观察组ECOG评分≥2级发生率为26.5%和12.0%,显著低于对照组56.5%和40.0%(P<0.05);在治疗48周时,观察组MELD评分为(9.7±1.3)分,显著低于对照组【(11.4±1.5)分,P<0.05】。结论采取PDF联合自体骨髓干细胞移植治疗HBV-ACLF患者可显著促进蛋白合成,降低病死率,提高ECOG评分。 展开更多
关键词 慢加急性乙型肝炎肝衰竭 自体骨髓干细胞移植 血浆透析滤过 美国东部肿瘤协作组评分 终末期肝病模型 疗效
下载PDF
Analysis of Use and Outcomes of Peripherally Inserted Central Catheter (PICC-Line) in Hemato-Oncological Patients
10
作者 Sulav Sapkota Radheshyam Naik 《Journal of Cancer Therapy》 2018年第1期35-41,共7页
Aims: To audit the use and outcomes of using PICC lines in hemato-oncological patients. Objectives: To study the demographics of patients: ?studying the use of PICC line in hemato-oncological patients;studying the rat... Aims: To audit the use and outcomes of using PICC lines in hemato-oncological patients. Objectives: To study the demographics of patients: ?studying the use of PICC line in hemato-oncological patients;studying the rate of complications in PICC line;studying the cause of early removal of PICC line. Methods: All PICCs inserted in adult hemato-oncological patients in Hematology and Medical Oncology Department of Health Care Global (HCG) Hospital were studied prospectively, as per the proforma, till PICCs were removed or patient expired and the pattern of complications were noted. Results: Eighty-four PICCs were inserted over a period of initial nine months and followed for a total of 1 year with three months post insertion duration for a total of 10,868 catheter-days (mean of 129 days i.e. 4.3 months, range: 1 to 288 days). The most common indication for PICC was chemotherapy (100%). Among them 19 (22%) PICCs had complications and 12 were removed at the rate of 1.1/1000 PICC-days. Complications with haematologic malignancies were more as compared to those with solid tissue malignancies. Conclusions: Despite significant complication rates, PICCs are a relatively safe and cost effective mode of establishing central venous access. 展开更多
关键词 Peripherally Inserted CENTRAL CATHETER (PICC) Vascular Access Device (VAD) Catheter-Related BLOODSTREAM Infection (CR-BSI) eastern cooperative oncology group performance status (ECOG PS) CENTRAL VENOUS CATHETER (CVC)
下载PDF
老年非霍奇金淋巴瘤患者老年综合评估评分的比较研究 被引量:9
11
作者 刘辉 高铭 +8 位作者 梅迪 韩惠秀 李江涛 白洁菲 张春丽 冯茹 魏建平 田园 王婷 《中华内科杂志》 CAS CSCD 北大核心 2018年第5期330-334,共5页
目的提供老年非霍奇金淋巴瘤(NHL)患者老年综合评估(CGA)评分的分布数据;对比美国东部肿瘤协作组(ECOG)体力状况评分与CGA评分的差异。方法将北京医院血液科2014年2月至2017年2月收治的≥60岁NHL患者进行CGA评分,包括日常生活... 目的提供老年非霍奇金淋巴瘤(NHL)患者老年综合评估(CGA)评分的分布数据;对比美国东部肿瘤协作组(ECOG)体力状况评分与CGA评分的差异。方法将北京医院血液科2014年2月至2017年2月收治的≥60岁NHL患者进行CGA评分,包括日常生活活动功能评定量表(ADL)、工具性日常生活活动功能评估量表(IADL)和改良老年疾病累计评分表(MCIRS-G),依据量表得分及年龄将患者分为适合组、不适合组和脆弱组。采用横断面研究,了解其临床特征,分析CGA评分分布,并对比ECOG体力状况评分与CGA评分的差异。结果64例老年NHL患者纳入研究。根据CGA评估,适合组占51.6%(33例),不适合组占12.5%(8例),脆弱组占35.9%(23例);大多数患者有合并症,其中心血管疾病、糖尿病、高血压病较为常见;在60~64岁较年轻的患者中仍有25%(3/12)的患者CGA评估为"脆弱",在≥80岁的高龄患者中"脆弱"比例达42.9%(6/14);ECOG体力状况评分≤1分的患者中仍有38.9%(21/54)存在CGA受损。结论依据CGA评估,60岁及以上NHL患者中近一半存在CGA受损;在ECOG体力状况评分≤1分的患者中仍有部分患者存在CGA受损,提示ECOG评分会低估老年NHL患者功能受损程度。 展开更多
关键词 老年人 淋巴瘤 非霍奇金 老年综合评估 美国东部肿瘤协作组(ECOG)体力 状况评分
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部